Maturational changes in the in vivo activity of CYP3A4 in the first months of life

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 7, 2006, Pages 303-308

  Allegaert, Karel ^a,b   Van den Anker, J N ^b,c   Debeer, A ^a   Cossey, V ^a   Verbesselt, R ^a   Tibboel, D ^b   Devlieger, H ^a   de Hoon, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

CYP3A4 activity; Maturation; Neonate; Ontogeny; Tramadol

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; NORTRAMADOL; O DEMETHYLTRAMADOL; TRAMADOL; UNCLASSIFIED DRUG;

AGE; ARTICLE; CHILD DEVELOPMENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVELOPMENTAL STAGE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG URINE LEVEL; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; INFANT; MEDICAL ASSESSMENT; MULTIPLE REGRESSION; TIME; URINALYSIS;

EID: 33745880062     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44303     Document Type: Article

References (21)

1. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: Part 1. Clin Pharmacokinet. 2002; 41: 959-998.
2. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr Nephrol. 2005; 20: 872-885.
3. Allegaert K, Tibboel D, Naulaers G, Tison D, De Jonge A, Van Dijk M, Vanhole C, Devlieger H. Systematic evaluation of pain in neonates: effect on the number of intravenous analgesics prescribed. Eur J Clin Pharmacol. 2003; 59: 87-90.
4. Allegaert K, van den Anker JN, Verbesselt R, de Hoon J, Vanhole C, Tibboel D, Devlieger H. O-demethylation of tramadol in the first months of life. Eur J Clin Pharmacol. 2005a; 61: 837-842.
5. Allegaert K, Anderson B, Verbesselt R, Debeer A, de Hoon J, Devlieger H, van den Anker JN, Tibboel D. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth. 2005b; 95: 231-239.
6. Allegaert K, Rayyan M, de Hoon J, Tibboel D, Verbesselt R, Naulaers G, van den Anker JN, Devlieger H. Contribution of glucuronidation to tramadol disposition in early neonatal life. Basic Clin Pharmacol Toxicol. 2006; 98: 110-112.
7. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999; 37: 485-505.
8. Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol. 2005; 61: 821-829.
9. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004; 43: 879-923.
10. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J Pharmacol Exp Ther. 2002; 300: 355-360.
11. Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000; 38: 53-60.
12. Johnson TN. Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. Towards an increased knowledge of paediatric clinical pharmacology. Eur J Clin Pharmacol. 2005; 61: 929-930.
13. Kanamori M, Takahashi H, Echizen H. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther. 2002; 40: 485-492.
14. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003a; 349: 1157-1167.
15. Kearns GL, Robinson PK, Wilson JT, Wilson- Costello D, Knight GR, Ward RM, van den Anker JN, Pediatric Pharmacology Research Unit Network. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther. 2003b; 74: 312-325.
16. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997; 247: 625-634.
17. Leeder JS, Gotshall RR, Gaedigk A, Adcock K, Wilson JT, Kearns GL. Acquisition of functional CYP2D6 and CYP3A4 activities in vivo in the first year of life. Drug Metab Rev. 2000; 32: 281 (abstract).
18. Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997; 53: 235-239.
19. Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther. 2005; 77: 458-467.
20. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000; 10: 187-216.
21. Tréluyer JM, Bowers G, Cazali N, Sonnier M, Rey E, Pons G, Cresteil T. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003; 31: 275-281.